1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Branded Generics: Strategies and Tactics for Winning in Latin America

Introduction

It’s a $66 billion market—and getting bigger every year. The time is ripe for action. Yet for all the appeal and potential returns of investing in Latin America’s burgeoning branded generics market, there are hurdles.

For pharma companies seeking entry into the diverse, complex and emerging Latin American market, challenges exist on all fronts. Consumers have an embedded preference for known brand names or cheap alternatives. The sector is increasingly becoming consolidated. Regulatory reforms continue to favour local manufacturers. And politics across borders are as diverse as official reimbursement policies.

Yet one thing remains constant: The moment to invest in the Latin American branded generics market has arrived.

Like a clear roadmap across complex terrain, Branded Generics: Strategies and Tactics for Winning in Latin America offers critical knowledge into how pharmaceutical companies can leverage their global experience into a region transitioning from sales to marketing models. Filled with on-point information and insights into everything from the importance of long-term commitment to building consumer loyalty amongst the rising middle class, the dossier lays bare the issues—and answers—to making profitable in-roads.


Scope

Key Benefits
The Latin American market promises much to those with a long-term commitment and a deep-seated understanding of regional needs. Understanding those needs is critical for success. While the hurdles are many—and constantly shift as governments change—an agile sales force and sophisticated messaging will gain the upper hand. Branded Generics: Strategies and Tactics for Winning in Latin America holds the key to ensuring that success. Amongst the benefits, this report will help you to:

• Understand how to gain access to the dynamic and evolving $66 billion Latin American pharmaceutical industry
• Build brand awareness through regional and national cultural tie-ins rather than direct-to-consumer advertising
• Encourage brand fidelity through loyalty programmes and ‘classic brand’ portfolios
• Leverage added-value services to combat bioequivalent and cheap alternatives
• Manage the threat from government-protected industries and avoid saturated markets


Highlights

Key Report Features
• Access to local industry experts with extensive operational experience in the Latin American branded generics markets
• Current intelligence about trends in regulation, pricing, IP and competition across various regions
• Up-to-date market data for billion-dollar branded pharma markets
• Case studies examining how successful companies build brand awareness through sports sponsorships and loyalty programmes
• Insights from innovator companies competing in hospital-driven niches, such as oncology


Reasons to Buy This Report

Key questions answered
• Who are the key stakeholders, now and going forward?
• How are branded generics defined in each country?
• What works best for marketing off-patent drugs?
• Who represents the greatest challenge—local manufacturers, large retailers or other pharmaceutical companies?
• What are the key elements to investing in local manufacturing and partnerships?

Key Quotes
“Buying a generics maker makes sense for large companies; they can optimise their supply chain and have one or two plants that make a lot of different products…but in Mexico it’s the small companies that have done well in generics.” Xavier Tello, Independent healthcare industry expert

“As a manufacturer, you should be committed to deliver your product and add value to society. But you also have the business question: in a high-risk market like Venezuela, you have to be there like you do in Brazil…but you also have to face reality.” Rodrigo Bonilla, Astellas Pharma

“Patients don’t often differentiate between an original product and a branded generic…most people think they are buying original products.” Karina Mendez, Market Access Manager for Merck Sharpe & Dohme, Argentina



Table Of Contents

Branded Generics: Strategies and Tactics for Winning in Latin America
1.Unique and detailed overview of the current marketplace ­ its drivers, key disease profiles and potential growth
2.Case studies outlining successful brand awareness and loyalty campaigns
3.Six critically important factors for ensuring success and how to employ them
4.Interviews with key people at global and local companies who have extensive operational experience in the region's branded drug markets
5.Pharmaceutical market data on five key Latin American markets

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.